Advertisement

Biotech SemBioSys has joint venture deal with Chinese pharmaceutical company

CALGARY – SemBioSys Genetics Inc. (TSX:SBS) said Tuesday it has signed an agreement with one of China’s largest pharmaceutical companies to sell its plant-based manufacturing technology.

The Calgary company said it has a joint venture agreement with Tasly Pharmaceuticals Ltd. under which SemBioSys will be entitled to 30 per cent ownership and profit sharing.

Get expert insights, Q&A on markets, housing, inflation, and personal finance information delivered to you every Saturday.

Get weekly money news

Get expert insights, Q&A on markets, housing, inflation, and personal finance information delivered to you every Saturday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

Tasly will contribute 100 per cent of the cost of the joint venture’s global research, development and product commercialization.

The new company created under the joint venture deal will develop and commercialize a variety of products for China and around the world.

SemBioSys is a biotechnology company develops high value proteins and oils and drug candidates for health and wellness products.

Tasly is China’s second largest producer of traditional Chinese medicines derived from plants.

Advertisement

Sponsored content

AdChoices